Addimmune is focused on pioneering a functional cure for HIV through innovative cell and gene therapy approaches. Their strategy leverages a deep understanding of the HIV genome and human biology to enhance the immune system's ability to combat the virus. Central to their technology is the use of lentiviral vectors, which facilitate the delivery of modifying microRNAs (miRNAs) directly into CD4 T cells. This process aims to block HIV's entry by targeting the CCR5 co-receptor, thereby preventing the virus from infecting these critical immune cells. Additionally, the therapy seeks to inhibit HIV replication within already infected cells, enhancing the overall immune response against the virus.

The company has conducted a Phase 1a clinical study to evaluate the safety and effectiveness of their AGT103-T treatment, which involves the infusion of modified T cells. Initial findings from this study have shown promising results, including the engraftment and functionality of the modified CD4 T cells, as well as a notable expansion of these cells post-infusion. Following this, Addimmune is exploring further studies, including an analytical treatment interruption (ATI) to assess the immune response when participants cease their antiretroviral therapy. The data collected from these trials will inform future clinical protocols and enhance the understanding of how to maximize the immune response against HIV.

United States

At Addimmune, our mission is to deliver the world’s first functional cure for HIV. Using viral vector delivery, we are seeking to give the immune system the tools it needs to resist and ultimately clear the virus.

Addimmune

Company Details